Product Description
For Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Auron Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer|Genital Cancer, Female|Prostate Cancer|Gastrointestinal Cancer
Phase 2: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00405873 |
AMT/P2GI/001 Part I | P2 |
Terminated |
Hepatocellular Carcinoma |
2010-03-01 |
2019-03-21 |
Treatments |
|
NCT00332280 |
AMT/P2CA/001 | P3 |
Terminated |
Genital Cancer, Female|Prostate Cancer|Gastrointestinal Cancer |
2010-01-01 |
2019-03-21 |
Treatments |
|
NCT00405561 |
AMT/P2GI/001 Part III | P3 |
Terminated |
Colorectal Cancer |
2010-01-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|